Long-term comparative and prospective cohort study of renal function in patients with HIV infection treated with tenofovir disoproxil fumarate

Calle, Guillermo Maestro de la; Pulido, Federico; Sánchez-Conde, Matilde; Quirós, Juan Carlos López Bernaldo de

doi:10.5114/hivar.2017.66859

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calle et al described a significant decline in renal function in a long term observational prospective cohort study studied over 7.5 years and attributed this change to the use of Tenofovir. 18 Kumarasamy et al described a similar relationship with Tenofovir use. 19 Mulenga et al also found in their adjusted analysis that patients receiving TDF were more likely to experience an episode of moderate or severe renal dysfunction than those receiving other regimens during the first year of ART, although the incidence of such episodes was low.…”

Section: Discussionmentioning

confidence: 90%

HIV positive patients on HAART continue to have a decline in renal function irrespective of Tenofovir usage: A 2-year cohort from an Indian tertiary care centre

Joshi

Jadhao

Gujarathi

et al. 2022

Preprint

View full text Add to dashboard Cite

Context: HIV patients may undergo renal damage due to disease or nephrotoxic drugs. Tenofovir has been associated with the development of renal impairment. Aims: To study and compare trends in Creatinine Clearance (CrCl) and estimated Glomerular Filtration Rate (eGFR) in patients on Highly Active Antiretroviral Therapy (HAART) and to compare the same between patients on Tenofovir and non-Tenofovir based regimens. Methods: A cross-sectional study was conducted. We followed 244 patients for a period of 2 years. The demographic, clinical, and laboratory parameters of the patients were recorded at baseline, one year of therapy, and two years of therapy. The data was analyzed by dividing patients into Tenofovir and non-Tenofovir based groups. Statistical analysis used the Chi-square test, paired and unpaired t-tests, and Fischers exact test. Results: The mean BUN and serum creatinine in both groups were comparable at the start of the therapy. The decline in CrCl and eGFR in all patients on HAART for two years was statistically significant, irrespective of Tenofovir usage. The mean fall in eGFR in the Tenofovir group was 12.4 mL/min/1.73 m2 and in the non-Tenofovir group, 9 mL/min/1.73 m2, though the differences between eGFR and CrCl were not significant between the two groups at any point. Conclusions: Even though HAART usage has been said to slow the decline in kidney function in PLHIV, patients who receive HAART still show a statistically significant decline in renal function parameters, akin to the observations of other such studies in low-resource settings.

show abstract

Section: Discussionmentioning

confidence: 90%

HIV positive patients on HAART continue to have a decline in renal function irrespective of Tenofovir usage: A 2-year cohort from an Indian tertiary care centre

Joshi

Jadhao

Gujarathi

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Human Immunodeficiency Virus-positive Patients on Highly Active Antiretroviral Therapy Continue to Have a Decline in Renal Function Irrespective of Tenofovir Usage

Joshi,

Jadhao,

Gujarathi

et al. 2024

Journal of Global Infectious Diseases

View full text Add to dashboard Cite

Introduction: Human immunodeficiency virus (HIV) patients may undergo renal damage due to disease or nephrotoxic drugs. Tenofovir has been associated with the development of renal impairment. The aim of this study was to compare trends in creatinine clearance (CrCl) and estimated glomerular filtration rate (eGFR) in patients on highly active antiretroviral therapy (HAART) and to compare the same between patients on tenofovir- and nontenofovir-based regimens. Methods: A prospective observational study was conducted. We followed 244 patients for 2 years. The demographic, clinical, and laboratory parameters of the patients were recorded at baseline, 1 year of therapy, and 2 years of therapy. The data were analyzed using dividing patients into tenofovir- and nontenofovir-based groups. Statistical analysis was performed using the Chi-square test, paired and unpaired t-tests, and Fisher’s exact test. Results: The mean blood urea nitrogen and serum creatinine in both groups were comparable at the start of the therapy. The decline in CrCl and eGFR in all patients on HAART for 2 years was statistically significant, irrespective of tenofovir usage. The mean decrease in eGFR in the tenofovir group was 12.4 mL/min/1.73 m2 and in the nontenofovir group, 9 mL/min/1.73 m2, though the differences between eGFR and CrCl were not significant between the two groups at any point. Conclusion: Even though previous studies have suggested that HAART usage can slow the decline in kidney function in people living with HIV, patients who receive HAART still show a statistically significant decline in renal function parameters, akin to the observations of other such studies in low-resource settings.

show abstract

Long-term comparative and prospective cohort study of renal function in patients with HIV infection treated with tenofovir disoproxil fumarate

Abstract: Introduction: Evidence regarding long-term evolution of renal function in patients with human immunodeficiency virus (HIV) infection treated with tenofovir disoproxil fumarate (TDF) is scarce and often retrospective.

Cited by 2 publications

References 26 publications

HIV positive patients on HAART continue to have a decline in renal function irrespective of Tenofovir usage: A 2-year cohort from an Indian tertiary care centre

HIV positive patients on HAART continue to have a decline in renal function irrespective of Tenofovir usage: A 2-year cohort from an Indian tertiary care centre

Human Immunodeficiency Virus-positive Patients on Highly Active Antiretroviral Therapy Continue to Have a Decline in Renal Function Irrespective of Tenofovir Usage

Contact Info

Product

Resources

About